Document Detail

Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.
Jump to Full Text
MedLine Citation:
PMID:  24962606     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
A patient with rheumatoid arthritis presented with increasing fatigue, fever, gingival bleeding, and petechial rash. Her symptoms started 1 week after the first injection of etanercept (Enbrel). Her only other medications (methotrexate and hydroxychloroquine) had been unchanged for years. Tests revealed severe pancytopenia and bone marrow aplasia. She recovered with supportive treatment within 12 days. The literature on serious blood dyscrasias associated with anti-tumor necrosis factor-α therapy is reviewed, an intriguing postulated mechanism is discussed, and selective patient monitoring is recommended.
Authors:
Natasha Kozak; Joshua Friedman; Ami Schattner
Related Documents :
7488276 - The elusive search for geographic clusters of systemic lupus erythematosus. critical re...
568886 - Sarcoidosis and its ophthalmic manifestations.
23403606 - A patient with multifocal tabetic arthropathy: a case report and review of literature.
17324836 - Coexistence of extensive calcification and membrano-cystic changes in lupus erythematos...
8734386 - The odyssey of orpheus: the evolution of solo singing.
24349836 - Endometrial osseous metaplasia: case report with literature review.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs in R&D     Volume:  14     ISSN:  1179-6901     ISO Abbreviation:  Drugs R D     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-06-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883647     Medline TA:  Drugs R D     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  155-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Drugs R D
Journal ID (iso-abbrev): Drugs R D
ISSN: 1174-5886
ISSN: 1179-6901
Publisher: Springer International Publishing, Cham
Article Information
Download PDF
© The Author(s) 2014
OpenAccess:
Electronic publication date: Day: 11 Month: 6 Year: 2014
pmc-release publication date: Day: 11 Month: 6 Year: 2014
Print publication date: Year: 2014
Volume: 14First Page: 155 Last Page: 158
PubMed Id: 24962606
ID: 4070464
Publisher Id: 50
DOI: 10.1007/s40268-014-0050-z

Etanercept-Associated Transient Bone Marrow Aplasia: A Review of the Literature and Pathogenetic Mechanisms
Natasha KozakAff1Aff2
Joshua FriedmanAff1Aff2
Ami SchattnerAff1Aff2 Address: 972-8-939-0330 amiMD@clalit.org.il
Department of Medicine, Kaplan Medical Center, POB 1, Rehovot, 76100 Israel
The Faculty of Medicine, Hebrew University and Hadassah, Jerusalem, Israel

Introduction

With the increasing use of agents that block the action of tumor necrosis factor (TNF)-α in the treatment of rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory conditions, recognition of serious adverse events assumes greater importance even when they are rare [1]. We report a patient with RA who presented with transient bone marrow (BM) aplasia associated with the first injection of etanercept, and review the literature on TNF-blocking agent-associated cytopenias.


Report of a Case

A 62-year-old woman was admitted with fatigue, fever (39 °C), gingival bleeding, and a rash over her legs.

She had a history of RA diagnosed 6 years prior when marked synovitis in more than ten large and small joints was found, associated with prolonged morning stiffness, elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and strongly positive rheumatoid factor and anti-citrullinated peptide antibodies (250 IU/ml and 76.6, respectively).

Her recent treatment included methotrexate (22.5 mg once a week with daily folic acid) started on diagnosis, hydroxychloroquine (200 mg daily) and a single first injection of etanercept (Enbrel® 50 mg) administered subcutaneously into the thigh 23 days prior to admission.

Previous treatment with leflunomide and adalimumab (Humira®) had failed and been discontinued months before etanercept was started.

No other medications were used, and even methotrexate and hydroxychloroquine were discontinued by her rheumatologist when etanercept was commenced.

One week after the injection, she reported malaise, lassitude, and low-grade fever; those symptoms persisted over 2 weeks.

A sudden appearance of high fever and rash led to her admission.

On admission, she was febrile and tachycardic but stable, with unrewarding examination except for gingival bleeding, a profuse petechial rash over both legs and polysynovitis, which was not new.

Laboratory tests showed hemoglobin (Hb) 7.5 g/dl (normocytic), WBC 1.8 × 109/L with absolute neutrophil count (ANC) 0.7 × 109/L, platelets 3 × 109/L, ESR 172 mm/h, CRP 76.8 mg/dL (normal <6 mg/dL), albumin 26 g/L, and globulins 47 g/L (polyclonal). Serum creatinine, electrolytes, and liver enzymes were normal. Peripheral blood smear confirmed severe pancytopenia with absent reticulocytes (0.3 %). Bone marrow aspiration and biopsy revealed BM aplasia (Fig. 1). Methotrexate in serum was undetectable. Chest X-ray, urinalysis, and cultures were normal. Tests for other causes of cytopenias, including serology for Epstein–Barr virus (EBV), cytomegalovirus (CMV), hepatitis viruses, parvovirus B-19, and HIV were negative.

The patient was treated with platelets (four times), packed cells (4 U), granulocyte colony-stimulating factor (Neupogen®) over 5 days, and broad-spectrum antibiotics. She was discharged on the 12th hospital day, afebrile and stable (absolute neutrophil count [ANC] 10.5 × 109/L), for ambulatory follow-up.

One month later, the Hb was 12.4 g/dL, white blood count (WBC) 13.7 × 109/L, and platelets 149 × 109/L. The patient resumed methotrexate treatment uneventfully for more than 6 months of follow-up.


Discussion and Review of the Literature

When serious adverse events (SAEs) associated with anti-TNFα therapy are considered, attention is usually focused on an increased risk of infections (in particular, reactivation of tuberculosis and opportunistic infections) and malignancy, though the latter remains an unresolved concern [2].

However, anti-TNFα therapy-induced cytopenias constitute another SAE that are potentially life threatening and mandate better recognition. For example, neutropenia was reported in 14.3–18.8 % of patients receiving a TNFα inhibitor [35]. In most of the patients, neutropenia occurred after just 2 weeks of treatment, was mild (mean −1.1 × 109/L), transient, and showed spontaneous resolution, allowing the original treatment to be continued in most (81 %) patients. However, a few patients developed serious secondary infections (4/367, 1.1 %) [5]. Notably, asymptomatic drops in platelet counts (mean −28 × 109/L) were often associated [5]. Indeed, 19 patients with significant thrombocytopenia were identified in a recent review of the literature and, as in the case of neutropenia, almost all were due to either etanercept or infliximab [6]. No other concomitant medication was reported in most of the patients. Rarely, patients may develop both severe neutropenia and thrombocytopenia [7], whereas anemia is not usually a feature of this treatment. On the contrary, with amelioration of the underlying disease on anti-TNFα therapy, the often-present anemia of chronic inflammation frequently improves [8]. However, this therapy, especially etanercept and infliximab, may mediate a more life-threatening adverse event than neutropenia or thrombocytopenia, namely, aplastic anemia and pancytopenia. A few such patients have been identified in post-marketing reports, although the attribution of pancytopenia to the TNF inhibitor remains unclear [9]. The characteristics of all fully reported cases are summarized in Table 1. Thus, etanercept and infliximab have been linked so far to just one case of aplastic anemia each, and several patients had developed pancytopenia or aplastic anemia, which could well have been related to anti-TNFα therapy [1116]. Most affected patients had RA, and the hematological SAE occurred predominantly after the first TNFα antagonist doses, becoming symptomatic soon after and usually responsive to drug discontinuation and supportive treatment (Table 1).

Our patient presented with symptoms and signs related to all three cytopenias: fatigue (due to anemia); fever that responded to broad spectrum antibiotics (due to severe neutropenia); and petechiae and gingival bleeding (due to severe thrombocytopenia). The absence of concomitant drugs (she had been receiving methotrexate and hydroxychloroquine for years) as well as the temporal relationship between the appearance of her symptoms and the first injection of etanercept, strongly suggest a causal link. Moreover, BM recovery from toxic injury corresponded to the discontinuation of etanercept, whereas methotrexate was later continued uneventfully for months. In contrast, in some of the other cases cited, drugs other than anti-TNFα could have been responsible.

Other than listing all hitherto-reported cases of TNF blocking agent-associated aplastic anemia and pancytopenia, the literature review reveals the rarity of the association, considering that hundreds of thousands of patients have been treated. The other striking feature is the complexity of the pathogenesis. TNFα is a pleiotropic cytokine, part of a complex cytokine network that regulates hematopoiesis and may affect BM stem cells differently under different circumstances [17, 18]. On one hand, TNFα (and interferon γ) are overexpressed in the BM of patients with acquired aplastic anemia and can be involved in BM stem cell apoptosis and suppression of erythropoiesis [19, 20]. Thus, treatment with TNFα antagonists can be a useful approach to the treatment of refractory aplastic anemia [2123]. On the other hand, under different conditions, TNFα interacting with other cytokines directly enhances the clonal growth of BM progenitors and suppresses hematopoietic stem cell apoptosis [17, 24]. Thus, its blockade can also exert a deleterious effect on hematopoiesis [6]. Since autoimmune mechanisms are believed to have a key role in the pathogenesis of idiopathic aplastic anemia [25], the association between TNF-targeted therapies and induction of autoimmune diseases (particularly, vasculitis and lupus predominantly with infliximab and etanercept) is also a tenable mechanism [26].

In conclusion, TNFα antagonists for the treatment of RA show significant benefit and are generally safe in comparison with other disease-modifying anti-rheumatic drugs [2729]. BM suppression resulting in severe cytopenia, transient pancytopenia, or aplastic anemia is a well established but fortunately rare SAE of anti-TNFα therapy. Since a steadily increasing number of patients are being treated for longer periods, any serious adverse effect, however rare, may be encountered.

Monitoring blood counts of patients starting treatment seems advisable, and we also suggest that patients should be instructed to consult their physician when unexplained fever, fatigue, or bleeding manifestations appear.


Conflict of interest

The authors confirm that they have no conflict of interest in connection with this manuscript.


References
1.. Hyrich KL,Silman AJ,Watson KD,Symmons DPM. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safetyAnn Rheum DisYear: 2004631538154310.1136/ard.2004.02473715242866
2.. Burmester G,Panaccione R,Gordon KB,et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s diseaseAnn Rheum DisYear: 20137251752410.1136/annrheumdis-2011-20124422562972
3.. Rajakulendran S,Gadsby K,Allen D,et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritisAnn Rheum DisYear: 2006651678167910.1136/ard.2006.05617617105865
4.. Bathon JM,Martin RW,Fleischmann RM,et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritisN Engl J MedYear: 20003431586159310.1056/NEJM20001130343220111096165
5.. Hastings R,Ding T,Butt S,et al. Neutropenia in patients receiving anti-tumor necrosis factor therapyArthritis Care Res (Hoboken)Year: 20106276476910.1002/acr.2003720535786
6.. Bessissow T,Renard M,Hoffman I,et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapyAliment Pharmacol TherYear: 20123631232310.1111/j.1365-2036.2012.05189.x22725726
7.. Vidal F,Fontova R,Richart C. Severe neutropenia and thrombocytopenia associated with infliximabAnn Intern MedYear: 2003139E238E23910.7326/0003-4819-139-3-200308050-00021-w4
8.. Furst DE,Kay J,Wasko MC,et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisRheumatology (Oxford)Year: 2013521845185510.1093/rheumatology/ket23323838027
9.. US FDA. Safety update on TNF-α antagonists: infliximab and etanercept. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf.
10.. Favalli EG,Varenna M,Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathyClin Exp RheumYear: 200523247250
11.. Quartier P,Taupinv P,Bourdeaut F,et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset typeArthritis RheumYear: 2003481093110110.1002/art.1088512687553
12.. Menon Y,Cucurulli E,Espinoza LR. Pancytopenia in a patient with scleroderma treated with infliximabRheumatologyYear: 2003421273127410.1093/rheumatology/keg34114508054
13.. Kuruvilla J,Leitch HA,Vickars L,et al. Aplastic anemia following administration of a tumor necrosis factor-α inhibitorEur J HaematolYear: 20037139639810.1034/j.1600-0609.2003.00115.x14667206
14.. Marchesoni A,Arreghini M,Panni B,Battafarano N,Uziel L. Life-threatening bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximabRheumatologyYear: 20034219319410.1093/rheumatology/key05112509641
15.. Seiderer J,Goke B,Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patientsDigestionYear: 2004703910.1159/00008007515297773
16.. Ben-Salem C, Jeddi C, Fathalla N, et al. Infliximab-induced bone marrow aplasia and vasculitis. In: ISoP 9th annual Meeting, Reims, France, 2009, Abstract 10.
17.. Jacobsen SE,Jacobsen FW,Fahlman C,Rusten LS. TNF-alpha, the great imitator: role of p55 and p75 TNF receptors in hematopoiesisStem CellsYear: 199412Suppl 11111267535144
18.. Schuettpelz LG, Link DC. Regulation of hematopoietic stem cell activity by inflammation. Front Immunol. 2013;4:204. doi:10.3389/fimmu.2013.00204. eCollection 2013.
19.. Dufour C,Corcione A,Svahn J,et al. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemiaBr J HaematolYear: 20011151023103110.1046/j.1365-2141.2001.03212.x11843845
20.. Hara T,Ando K,Tsurumi H,Moriwaki H. Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemiaEur J HaematolYear: 200473101610.1111/j.1600-0609.2004.00259.x15182332
21.. Dufour C,Ferretti E,Bagnasco F,et al. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemiaHaematologicaYear: 2009941743174710.3324/haematol.2009.00781519586939
22.. Dufour C,Giacchino R,Ghezzi P,et al. Etanercept as a salvage treatment for refractory aplastic anemiaPediatr Blood CancerYear: 20095252252510.1002/pbc.2188619061218
23.. Fureder W,Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approachesLeuk LymphomaYear: 2011521435144510.3109/10428194.2011.56864621635205
24.. Rezzoug F,Huang Y,Tanner MK,et al. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and functionJ ImmunolYear: 2008180495710.4049/jimmunol.180.1.4918097003
25.. Young NS,Scheinberg P,Calado RT. Aplastic anemiaCurr Opin HematolYear: 20081516216810.1097/MOH.0b013e3282fa747018391779
26.. Ramos-Casals M,Brito-Zeron P,Munoz S,et al. Autoimmune diseases induced by TNF-targeted therapiesMedicineYear: 20078624225110.1097/MD.0b013e3181441a6817632266
27.. Wiens A,Venson R,Correr CJ,Otuki MF,Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritisPharmacotherapyYear: 20103033935310.1592/phco.30.4.33920334454
28.. Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Databases Syst Rev. 2013;(5):CD004525.
29.. Murdaca G,Spano F,Contratore M,et al. Efficacy and safety of etanercept in chronic immune-mediated diseaseExpert Opin Drug SafYear: 20141364966110.1517/14740338.2014.89957924654562

Figures

[Figure ID: Fig1]
Fig. 1 

Patient’s bone marrow biopsy showing stroma and plasma cells (more resistant to drug toxicity) but absence of all other hematopoietic elements, consistent with transient aplasia



Tables
[TableWrap ID: Tab1] Table 1 

Potentially life-threatening non-malignant hematological complications associated with tumor necrosis factor-inhibitor therapy


Patients
References
Background Treatment Other potential drugs SAEs Time interval Outcome Remarks
4/367 pts
[5]
Varied Varied Unlikely Severe neutropenia with serious infection NR Recovered BM ‘normal’ in 2 cases
20M
[10]
Crohn’s spondylarthritis Infliximab [2nd] None Agranulocytosis NR Resolved, recurred after retreatment Granulocyte Bound Ab and neutrophil-specific bound Ab
60F
[7]
RA Infliximab [3rd] Unlikely Fever/chills and skin hemorrhages: profound neutropenia and thrombocytopenia 7 weeks Resolved BM Bx: hypoplasia
2/61 pts
[11]
Juvenile Id. arthritis Etanercept [1st in 1 pt] Unlikely Pancytopenia 0.5; 12 months Resolved Open-label prospective study
45F
[12]
Scleroderma Infliximab [1st] None Severe pancytopenia and candida peritonitis 3 weeks Died Transient HS reaction at 6 days
78M
[13]
RA Etanercept (>17th dose) Unlikely Aplastic anemia and sepsis <3 months Resolved over 3 weeks BM Bx+
66M
[14]
RA Infliximab [1st] Possible Severe pancytopenia and BM hypoplasia with sepsis 10 days Resolved over 2 weeks BM Bx+
32F
[15]
Colitis Infliximab [1st] Possible (IV ATB) Severe pancytopenia 6 days Resolved over 2 weeks
32NR
[16]
Ankylosing spondylitis Infliximab [1st] None Aplastic anemia 4 days Resolved over 16 days Associated skin vasculitis BM Bx+
62F
Current
RA Etanercept [1st] Unlikely Transient BM aplasia 2 weeks Resolved over 12 days BM Bx+

Ab antibodies, BM bone marrow, Bx biopsy, F female, HS hypersensitivity, Id. idiopathic, IV ATB intravenous antibiotics, M male, NR not reported, pt(s) patient(s), RA rheumatoid arthritis, SAE serious adverse event, + postive



Article Categories:
  • Short Communication


Previous Document:  Design, Synthesis, Physicochemical Studies, Solvation, and DNA Damage of Quinoline-Appended Chalcone...
Next Document:  A Double-blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for...